Aerami’s upcoming merger with FoxWayne will bolster the company’s PAH portfolio
Proceeds from Aerami’s merger with FoxWayne will help advance the development of the company’s PAH therapy, AER-901 (imatinib).
M&A Review Financial Advisor League Tables - Academic
Aerami’s upcoming merger with FoxWayne will bolster the company’s PAH portfolio
Alvotech and Oaktree enter merger deal to form biopharma company
Drug developer BenevolentAI enters SPAC merger deal with Odyssey
Amgen concludes acquisition of biotech company Teneobio for $2.5bn
Sanofi concludes acquisition of Translate Bio for $3.2bn
EQRx signs $1.8bn merger deal with CM Life Sciences III
AstraZeneca concludes Alexion acquisition for $39bn
